Loading...
Ce produit n'est pas destiné à diagnostiquer, traiter, guérir ou prévenir toute maladie. Ces déclarations n'ont pas été évaluées par la Food and Drug Administration.
Loading...
Ces informations sont fournies à titre éducatif uniquement et ne remplacent pas un avis médical professionnel, un diagnostic ou un traitement. Consultez toujours votre professionnel de santé avant d'utiliser des plantes, surtout si vous êtes enceinte, allaitez, prenez des médicaments ou avez une condition médicale.
Viscum album
Une plante semi-parasite sacrée pour les Druides, maintenant largement étudiée en oncologie intégrative européenne.
European Mistletoe (Viscum album) is a semi-parasitic plant with a long history in traditional European medicine, now primarily used in integrative oncology for its immunomodulatory and antiproliferative properties. Its key active compounds include viscotoxins, mistletoe lectins (ML-I, ML-II), flavonoids, and triterpene acids, which contribute to its therapeutic effects. Evidence is limited (Level C) but supports its use as an adjunct in cancer therapy, particularly in injectable forms like Iscador.
Mistletoe lectins (especially ML-I) bind to cell surface glycoproteins and glycolipids, inducing apoptosis and immunostimulation via activation of caspases and NF-κB pathways. Viscotoxins form ion channels in cell membranes, leading to cytotoxicity. Flavonoids and triterpene acids contribute antioxidant and anti-inflammatory effects. The immunomodulatory action involves increased natural killer cell activity and cytokine release (e.g., IL-1, IL-6, TNF-α).
Une plante semi-parasite sacrée pour les Druides, maintenant largement étudiée en oncologie intégrative européenne.
European Mistletoe (Viscum album) is a semi-parasitic plant with a long history in traditional European medicine, now primarily used in integrative oncology for its immunomodulatory and antiproliferative properties. Its key active compounds include viscotoxins, mistletoe lectins (ML-I, ML-II), flavonoids, and triterpene acids, which contribute to its therapeutic effects. Evidence is limited (Level C) but supports its use as an adjunct in cancer therapy, particularly in injectable forms like Iscador.
Mistletoe lectins (especially ML-I) bind to cell surface glycoproteins and glycolipids, inducing apoptosis and immunostimulation via activation of caspases and NF-κB pathways. Viscotoxins form ion channels in cell membranes, leading to cytotoxicity. Flavonoids and triterpene acids contribute antioxidant and anti-inflammatory effects. The immunomodulatory action involves increased natural killer cell activity and cytokine release (e.g., IL-1, IL-6, TNF-α).